ELMMB logo
Facebook logo Twitter logo
Menu
Drug Alerts and Withdrawals

Drug Alerts and Withdrawals

Within the UK, the Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health aim to enhance and safeguard the health of the public by ensuring that medicines and medical devices work and are acceptably safe. No product is risk-free. Underpinning their work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.

  • The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe.
  • No product is risk-free. Underpinning the work of the MHRA lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.
  • The MHRA keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem.
  • The MHRA aim to make as much information as possible publicly available. The MHRA enable greater access to products, and the timely introduction of innovative treatments and technologies that benefit patients and the public.
  • The MHRA encourage everyone - the public and healthcare professionals as well as industry - to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action. To find out more about the MHRA click here...

When the MHRA, or occasionally another regulatory body in another country, such as the FDA, release advice, it is sometime necessary to produce additional local guidance.  This aims to be both clear and concise advice to healthcare professionals on the local action required to implement or respond to alerts issued by the MHRA or other bodies.  These memorandums are available below for reference, once they have been circulated to the relevant professionals in primary and secondary care:

MHRA News Stories.

 26th May 2020              MHRA Press Release - MHRA supports use of remdesivir as the first medicines to treat COVID-19 in the UK
 6th May 2020                MHRA Press Release - NEW Yellow Card COVID-19 reporting site
12th February 2020      MHRA Press Release  - Integrated Yellow Card reporting now available in 93% of GP practices in the UK
19th November 2019   MHRA Press Release - Ranitidine Oral Solution & Tablets recall
                                                     
                                                 


MHRA Company-led Drug alerts

click here to access the most recent alerts

Items In This Category

 TitleCreatedDownload
application/pdfOzurdex Intravitreal Implant in Applicator recall Allergan UK_Final_-DHPC_180319.pdf (69KB)18/03/2019Download
 Allergan Pharmaceuticals Ireland is further recalling batches due to the possibility that a single loose silicone particle of approximately 300 microns in diameter may become detached.  
application/pdfAtropine Sulfate 3mg per 10ml Soln for injection in pfs EL 19 A05 Final.pdf (151KB)18/02/2019Download
 Aguettant Limited has informed the MHRA that there is an error in the Patient Information Leaflet (PIL) for batches of the above product listed above. In Section 6 of the Leaflet included in these... 
application/pdfIrbesartan Class 2 medicines recall Actavis Group EL_19_A04-Final.pdf (163KB)14/02/2019Download
  
application/pdfIrbesartan 150mg Class 2 medicines recal EL__19_A02_Final.pdf (164KB)24/01/2019Download
 Macleods Pharma UK Limited is recalling the above batches from pharmacies as a precautionary measure due to possible contamination with N‑nitrosodiethylamine (NDEA). 
application/pdfIrbesartan hydrochlorothiazide Class 2 medicines recall MHRA.pdf (163KB)03/01/2019Download
 Class 2 Medicines Recall: Actavis Group PTC EHF – recall of batches of Irbesartan/Hydrochlorothiazide 300/12.5mg Film-coated Tablets and Irbesartan/Hydrochlorothiazide 150/12.5mg Film-coated Tablets 
application/pdfLidocaine teething products: talk to your pharmacist -patient-sheet.pdf (88KB)13/12/2018Download
 Key messages for parents and caregivers 
application/pdfValsartan Class 2 medicines recall 301118 MHRA.pdf (167KB)30/11/2018Download
 Teva is recalling the listed batches and Mylan is recalling all unexpired batches of the above products from pharmacies as a precautionary measure at a European level due to possible contamination... 
application/pdfOzurdex 700mcg intravitreal implant in applicator Class 2 medicines recall MHRA Final 0518.pdf (262KB)05/10/2018Download
 Allergan Pharmaceuticals Ireland is recalling some batches in the attached alert due to the possibility that a single loose silicone particle of approximately 300microns in diameter may become... 
application/pdfSodium Cromoglicate & Murine hayfever relief eye drops Class 3 medicines recall EL_18_A13-Final.pdf (132KB)31/07/2018Download
 FDC International Ltd is recalling the above batches due to the presence of a precipitate, which has been identified as Sodium Cromoglicate, in some bottles. 
application/pdfValsartan Class 1 medicines recall EL_18_A_11-_revision_1.pdf (62KB)11/07/2018Download
 The Drug Alert EL (18)A/11 issued on 5 July 2018 is now superseded by this revised alert EL (18)A/11 – revision 1 because Actavis (now Accord) has provided new information that an additional product... 
application/pdfFiasp FlexTouch 100units per mL class 2 medicines recall 090718.pdf (31KB)09/07/2018Download
 Novo Nordisk is recalling one batch as a precautionary measure due to the presence of particles in a small number of samples. 
application/pdfValsartan Class 1 Medicines Recall ACTION NOW 050718 EL_18_A_11.pdf (62KB)06/07/2018Download
 Valsartan Class 1 Medicines Recall ACTION NOW Pharmacies in the UK are being advised to recall all batches of valsartan containing medicines made by Dexcel Pharma Ltd and Accord Healthcare... 
Page: [1] [2] [3] [4] [5] [6]